Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million
Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent
Alfasigma completes acquisition of Intercept Pharmaceuticals, Inc.
Alfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.
Alfasigma signs a letter of intent to acquire the Jyseleca® business from Galapagos, expanding its European presence through an innovative product specializing in the rheumatology and gastrointestinal areas
Alfasigma S.p.A. tender offer for Intercept Pharmaceuticals, Inc. commences